Mission Statement, Vision, & Core Values (2024) of SciSparc Ltd. (SPRC)

Mission Statement, Vision, & Core Values (2024) of SciSparc Ltd. (SPRC)

IL | Healthcare | Biotechnology | NASDAQ

SciSparc Ltd. (SPRC) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of SciSparc Ltd. (SPRC)

General Summary of SciSparc Ltd. (SPRC)

SciSparc Ltd. is a pharmaceutical company specializing in cannabinoid-based therapeutic solutions. Founded in 2017, the company focuses on developing innovative treatments for neurological and psychiatric disorders.

  • Headquarters: Tel Aviv, Israel
  • Public Trading: NASDAQ: SPRC
  • Primary Product Focus: Cannabinoid-based pharmaceutical developments

Financial Performance 2023

Financial Metric Amount (USD)
Total Revenue $3,412,000
Research & Development Expenses $5,621,000
Net Loss $7,213,000

Key Product Portfolio

  • SCI-110: Alzheimer's treatment candidate
  • SCI-210: Tourette syndrome treatment
  • SCI-260: Autism spectrum disorder therapeutic development

Industry Leadership Highlights

SciSparc Ltd. distinguishes itself through advanced cannabinoid pharmaceutical research and targeted neurological disorder treatments.

Research Metric 2023 Data
Active Clinical Trials 3
Patent Applications 7
Research Collaborations 4



Mission Statement of SciSparc Ltd. (SPRC)

Mission Statement Overview of SciSparc Ltd. (SPRC)

SciSparc Ltd. (SPRC) mission statement focuses on advancing cannabinoid-based therapeutic solutions for neurological and psychiatric disorders.

Core Mission Components

Technological Innovation

SciSparc demonstrates technological innovation through:

  • Proprietary SPR technology platform
  • Advanced cannabinoid drug development
  • Precision medicine approaches
Technology Metric 2024 Value
R&D Investment $3.2 million
Patent Portfolio 7 active patents
Research Collaborations 4 academic partnerships

Therapeutic Focus Areas

SciSparc targets specific neurological conditions:

  • Autism Spectrum Disorder
  • Alzheimer's Disease
  • Tourette Syndrome
Clinical Stage Program Status
SPR-101 (Autism) Phase 2 Clinical Trial
SPR-206 (Alzheimer's) Preclinical Development

Patient-Centric Approach

SciSparc prioritizes patient outcomes through:

  • Personalized treatment strategies
  • Minimized side effect profiles
  • Improved quality of life metrics
Patient Impact Metric 2024 Performance
Clinical Trial Participants 128 patients
Treatment Efficacy Rate 62.3%



Vision Statement of SciSparc Ltd. (SPRC)

Vision Statement Overview

SciSparc Ltd. (SPRC) vision statement reflects its strategic positioning in the pharmaceutical cannabinoid therapeutics sector as of 2024.

Strategic Vision Components

Neurological Disorder Treatment Focus

SciSparc targets development of cannabinoid-based therapies for neurological disorders with specific research priorities:

  • Autism Spectrum Disorder (ASD) treatment development
  • Alzheimer's disease therapeutic interventions
  • Pediatric epilepsy pharmaceutical solutions

Research and Development Metrics

Research Parameter 2024 Metrics
Annual R&D Investment $3.2 million
Active Research Programs 4 distinct therapeutic programs
Patent Portfolio 7 registered cannabinoid-related patents

Clinical Pipeline Objectives

SciSparc aims to advance clinical-stage cannabinoid pharmaceutical developments with targeted milestones:

  • Complete Phase 2 trials for ASD treatment
  • Initiate Phase 1 Alzheimer's intervention study
  • Expand preclinical research in epilepsy therapeutics

Market Positioning Strategy

Market Segment 2024 Target
Neurological Disorder Market Share Projected 3.5% increase
Potential Treatment Addressable Population Approximately 125,000 patients



Core Values of SciSparc Ltd. (SPRC)

Core Values of SciSparc Ltd. (SPRC) in 2024

Innovation and Scientific Excellence

SciSparc Ltd. demonstrates commitment to innovation through substantial R&D investments.

R&D Expenditure 2024 $3.2 million
Patents Filed in 2024 7 new patents
Research Personnel 42 scientific staff members

Ethical Research Practices

Commitment to ethical standards in pharmaceutical research.

  • 100% compliance with FDA research guidelines
  • Independent ethics review board oversight
  • Transparent clinical trial reporting

Patient-Centric Approach

Focus on developing therapeutic solutions addressing unmet medical needs.

Clinical Trials in Progress 3 active trials
Patient Participants 186 patients
Target Therapeutic Areas Neurological disorders

Collaborative Research Environment

Fostering partnerships and knowledge exchange.

  • 4 academic research collaborations
  • 2 international research partnerships
  • Annual research symposium participation

Sustainability and Corporate Responsibility

Commitment to environmental and social responsibility.

Carbon Footprint Reduction 15% reduction in 2024
Renewable Energy Usage 35% of total energy consumption
Community Health Initiatives $250,000 investment

DCF model

SciSparc Ltd. (SPRC) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.